In a previous phase II study, the addition of cetuximab, a chimeric anti‐EGFR monoclonal antibody, to gemcitabine‐oxaliplatin did not yield a survival benefit in patients with advanced CCA. The gene discussed is EGFR; the disease is cholangiocarcinoma.